Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play

Investing.comMay 22, 2025 12:26 AM

View all comments（0）



Investing.com-- French pharmaceutical giant Sanofi SA (EPA:SASY) said on Wednesday it had entered an agreement to buy U.S.-listed biotech firm Vigil Neuroscience Inc (NASDAQ:VIGL), with focus chiefly on an early-stage Alzheimer’s drug being developed by the firm.

Sanofi will pay $8 in cash for each share in Vigil, representing a 246% premium to the latter’s close on Wednesday. Sanofi said the deal is at an enterprise value of $470 million- a massive premium to Vigil’s current market capitalization of around $115 million.

Additionally, Sanofi will also pay Vigil shareholders $2 per share in cash on the first commercial sale of its Alzheimer’s drug- VG-3927.

VG-3927 is an early-stage drug that is set to be evaluated in a phase 2 clinical study in Alzheimer’s disease. The drug is intended to improve the neuroprotective function of microglia- specialized immune cells in the nervous system- to help against Alzheimer’s.

Sanofi had invested $40 million in Vigil in 2024 that granted it exclusive rights to VG-3927. The drug is targeted at helping the brain stop and reverse damage from the neurodegenerative disease.

Alzheimer’s is the most common form of dementia, with data from Alzheimer’s Association stating that at least 7.2 million Americans aged 65 and older are living with the disease in 2025.

Currently, about five Alzheimer’s therapies have been approved by the U.S. Food and Drug Administration- Rivastigmine by Novartis (LON:0QLR) (SIX:NOVN), Galantamine developed by a unit of Johnson&Johnson (NYSE:JNJ), Donepezil by Pfizer (NYSE:PFE), AbbVie Inc ’s (NYSE:ABBV) Memantine, and Eli Lilly and Company’s (NYSE:LLY) Kisluna.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

SK Hynix Surges Over 4% as Q3 Results Hit Record High, Returning $75 Billion to Shareholders

SK Hynix reported a record-breaking Q3 operating profit while announcing a massive 100 trillion won (approximately $75 billion) shareholder return plan, sending its stock price surging 4%.

Today’s Market Recap: $63 Billion Anthropic Compute Financing Lifts Chip Stocks, Broadcom Gains 4%, CRWV Rises Nearly 8%, Boeing Falls Over 10%

TradingKey - On October 27, Eastern Time, all three major U.S. stock indexes closed higher, with the Nasdaq and the S&P 500 gaining for the second consecutive trading day. AI-related stocks continued to lead the rally, while a $63 billion computing power financing deal involving Broadcom (AVGO) lift

KOSPI Tops 5,800, Kioxia Jumps Over 4% as SK Hynix Revenue and Profit Hit Record Highs

The KOSPI surged over 3%, Kioxia jumped 4%, Samsung and SoftBank joined the rally, and SK Hynix unveiled a massive 100 trillion KRW in shareholder returns.

US Stocks Close: Nasdaq Rises Over 1%, Philadelphia Semiconductor Index Gains Over 3%; Chip Stocks Extend Rally, CoreWeave Gains Nearly 8%

On Tuesday, October 27, Eastern Time, U.S. stocks moved higher, with chip stocks extending their rally to drive the Nasdaq to lead the gains. Amid falling oil prices, investors continued to assess a heavy slate of corporate earnings reports while focusing on the Federal Reserve's interest rate meeting. At the close, the Dow Jones Industrial Average rose 0.03% to 52,377.57 points; the Nasdaq Composite Index gained 1.18% to 26,477.81 points; and the S&P 500 Index advanced 0.60% to 7,722.60 points.

Amazon Q3 Earnings Preview: AWS Growth Expected to Rise to 41%, Wall Street Top Price Target $400

TradingKey - Amazon (AMZN) will release its third-quarter 2026 financial results after the U.S. market close on October 29, Eastern Time, and hold an earnings conference call at 17:00 on the same day.

Featured Tools